BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

.../ MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) Ibudilast ALS Ph IIb/III planned Tumor necrosis factor (TNF) α ArmaGen Inc....
BioCentury | Mar 9, 2018
Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

...in severe MPS I patients that have not undergone successful hematopoietic stem cell transplantation (HSCT). ArmaGen...
...INSR) has rare pediatric disease and Fast Track designations in the U.S. for the indication. ArmaGen Inc....
...as measured by forced vital capacity (FVC) Status: Additional Phase I/II data Milestone: NA Jaime De Leon AGT-181 HIRMAb-IDUA ArmaGen Inc. Insulin...
BioCentury | Apr 27, 2017
Clinical News

AGT-181: Preliminary Ph I/II AGT-181-101 data

...In February, ArmaGen reported preliminary data from 5 children ages ≥2 with Hurler syndrome who had...
...improvement in shoulder range of motion. Data were presented at WORLD Symposium in San Diego. ArmaGen Inc....
...MRI neuroimaging parameters Status: Preliminary Phase I/II data Milestone: Start pivotal trial (year end 2017) Alex Himes AGT-181 HIRMAb-IDUA ArmaGen Inc. Alpha-L-iduronidase...
BioCentury | Aug 1, 2016
Clinical News

AGT-182: Phase I/IIa data

...treatment-related adverse events included anxiety, headache, throat itchiness, lightheadedness, nausea, jitters, clammy hands and weakness. ArmaGen...
...develop and commercialize AGT-182 from ArmaGen under a 2014 deal (see BioCentury, July 28, 2014). ArmaGen Inc....
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...D1 Resolvin derived from the oxidation of the omega-3 fatty acid docosahexaenoic acid (DHA) Preclinical ArmaGen Inc....
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...and internally in Hunter syndrome with Elaprase , our intrathecal program, and our partnership with ArmaGen."...
...MPS II patients with significant CNS symptoms. In 2014, Shire gained exclusive, worldwide rights from ArmaGen Inc....
...the clinic, including pacritinib for myelofibrosis and rigosertib for myelodysplastic syndrome. Companies and Institutions Mentioned ArmaGen Inc....
BioCentury | Nov 16, 2015
Clinical News

HIRMAb-IDUA regulatory update

...FDA granted rare pediatric disease designation to AGT-181 from ArmaGen to treat mucopolysaccharidosis I (MPS I...
...would be eligible for a transferrable Priority Review voucher for a subsequent NDA or BLA. ArmaGen Inc....
BioCentury | Sep 21, 2015
Clinical News

HIRMAb-IDUA: Phase I/IIa started

...and 6-9 mg/kg IV AGT-181 once weekly for 8 weeks in about 9 adult patients. ArmaGen Inc....
BioCentury | Jul 27, 2015
Company News

ArmaGen, Shire deal

...ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment from Shire under a 2014...
...iduronate-2-sulfatase ( IDS ) formulated with ArmaGen’s Trojan horse technology (see BioCentury, July 28, 2014) ArmaGen...
BioCentury | Jul 13, 2015
Clinical News

AGT-182: Phase I started

...8 weeks in about 12 patients. The trial start triggered an undisclosed milestone payment to ArmaGen...
...granting Shire exclusive, worldwide rights to develop and commercialize AGT-182 (see BioCentury, July 28, 2014). ArmaGen Inc....
Items per page:
1 - 10 of 33
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

.../ MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) Ibudilast ALS Ph IIb/III planned Tumor necrosis factor (TNF) α ArmaGen Inc....
BioCentury | Mar 9, 2018
Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

...in severe MPS I patients that have not undergone successful hematopoietic stem cell transplantation (HSCT). ArmaGen...
...INSR) has rare pediatric disease and Fast Track designations in the U.S. for the indication. ArmaGen Inc....
...as measured by forced vital capacity (FVC) Status: Additional Phase I/II data Milestone: NA Jaime De Leon AGT-181 HIRMAb-IDUA ArmaGen Inc. Insulin...
BioCentury | Apr 27, 2017
Clinical News

AGT-181: Preliminary Ph I/II AGT-181-101 data

...In February, ArmaGen reported preliminary data from 5 children ages ≥2 with Hurler syndrome who had...
...improvement in shoulder range of motion. Data were presented at WORLD Symposium in San Diego. ArmaGen Inc....
...MRI neuroimaging parameters Status: Preliminary Phase I/II data Milestone: Start pivotal trial (year end 2017) Alex Himes AGT-181 HIRMAb-IDUA ArmaGen Inc. Alpha-L-iduronidase...
BioCentury | Aug 1, 2016
Clinical News

AGT-182: Phase I/IIa data

...treatment-related adverse events included anxiety, headache, throat itchiness, lightheadedness, nausea, jitters, clammy hands and weakness. ArmaGen...
...develop and commercialize AGT-182 from ArmaGen under a 2014 deal (see BioCentury, July 28, 2014). ArmaGen Inc....
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...D1 Resolvin derived from the oxidation of the omega-3 fatty acid docosahexaenoic acid (DHA) Preclinical ArmaGen Inc....
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...and internally in Hunter syndrome with Elaprase , our intrathecal program, and our partnership with ArmaGen."...
...MPS II patients with significant CNS symptoms. In 2014, Shire gained exclusive, worldwide rights from ArmaGen Inc....
...the clinic, including pacritinib for myelofibrosis and rigosertib for myelodysplastic syndrome. Companies and Institutions Mentioned ArmaGen Inc....
BioCentury | Nov 16, 2015
Clinical News

HIRMAb-IDUA regulatory update

...FDA granted rare pediatric disease designation to AGT-181 from ArmaGen to treat mucopolysaccharidosis I (MPS I...
...would be eligible for a transferrable Priority Review voucher for a subsequent NDA or BLA. ArmaGen Inc....
BioCentury | Sep 21, 2015
Clinical News

HIRMAb-IDUA: Phase I/IIa started

...and 6-9 mg/kg IV AGT-181 once weekly for 8 weeks in about 9 adult patients. ArmaGen Inc....
BioCentury | Jul 27, 2015
Company News

ArmaGen, Shire deal

...ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment from Shire under a 2014...
...iduronate-2-sulfatase ( IDS ) formulated with ArmaGen’s Trojan horse technology (see BioCentury, July 28, 2014) ArmaGen...
BioCentury | Jul 13, 2015
Clinical News

AGT-182: Phase I started

...8 weeks in about 12 patients. The trial start triggered an undisclosed milestone payment to ArmaGen...
...granting Shire exclusive, worldwide rights to develop and commercialize AGT-182 (see BioCentury, July 28, 2014). ArmaGen Inc....
Items per page:
1 - 10 of 33